Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

Andrea Gaedigk to Humans

This is a "connection" page, showing publications Andrea Gaedigk has written about Humans.

 
Connection Strength
  
 
 
5.543
  
  1. Turner AJ, Haidar CE, Yang W, Boone EC, Offer SM, Empey PE, Haddad A, Tahir S, Scharer G, Broeckel U, Gaedigk A. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci. 2024 Jan; 17(1):e13699.
    View in: PubMed
    Score: 0.099
  2. Zubiaur P, Leeder JS, Abad-Santos F, Gaedigk A. Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?" Clin Pharmacol Ther. 2024 Feb; 115(2):184.
    View in: PubMed
    Score: 0.098
  3. Turner AJ, Nofziger C, Ramey BE, Ly RC, Bousman CA, Ag?ndez JAG, Sangkuhl K, Whirl-Carrillo M, Vanoni S, Dunnenberger HM, Rua?o G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Moyer AM, Gaedigk A. PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting. Clin Pharmacol Ther. 2023 Dec; 114(6):1220-1237.
    View in: PubMed
    Score: 0.097
  4. Gaedigk A, Boone EC, Turner AJ, van Schaik RHN, Chernova D, Wang WY, Broeckel U, Granfield CA, Hodge JC, Ly RC, Lynnes TC, Mitchell MW, Moyer AM, Oliva J, Kalman LV. Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project. J Mol Diagn. 2023 09; 25(9):655-664.
    View in: PubMed
    Score: 0.095
  5. Zubiaur P, Gaedigk A. CYP2C18: the orphan in the CYP2C family. Pharmacogenomics. 2022 11; 23(17):913-916.
    View in: PubMed
    Score: 0.091
  6. Ramsey LB, Gong L, Lee SB, Wagner JB, Zhou X, Sangkuhl K, Adams SM, Straka RJ, Empey PE, Boone EC, Klein TE, Niemi M, Gaedigk A. PharmVar GeneFocus: SLCO1B1. Clin Pharmacol Ther. 2023 04; 113(4):782-793.
    View in: PubMed
    Score: 0.089
  7. Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Dr?gem?ller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A. PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther. 2022 12; 112(6):1159-1171.
    View in: PubMed
    Score: 0.087
  8. Gaedigk A, Boone EC, Scherer SE, Lee SB, Numanagic I, Sahinalp C, Smith JD, McGee S, Radhakrishnan A, Qin X, Wang WY, Farrow EG, Gonzaludo N, Halpern AL, Nickerson DA, Miller NA, Pratt VM, Kalman LV. CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. J Mol Diagn. 2022 04; 24(4):337-350.
    View in: PubMed
    Score: 0.087
  9. Dinh JC, Boone EC, Staggs VS, Pearce RE, Wang WY, Gaedigk R, Leeder JS, Gaedigk A. The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity. Clin Pharmacol Ther. 2022 03; 111(3):646-654.
    View in: PubMed
    Score: 0.085
  10. Ramsey LB, Gaedigk A. CYP2D6*9 and *41: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype? Clin Pharmacol Ther. 2022 06; 111(6):1208-1211.
    View in: PubMed
    Score: 0.084
  11. Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 09; 110(3):662-676.
    View in: PubMed
    Score: 0.083
  12. Gaedigk A, Casey ST, Whirl-Carrillo M, Miller NA, Klein TE. Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clin Pharmacol Ther. 2021 09; 110(3):542-545.
    View in: PubMed
    Score: 0.083
  13. Hongkaew Y, Wang WY, Gaedigk R, Sukasem C, Gaedigk A. Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes. Pharmacogenomics. 2021 06; 22(9):529-541.
    View in: PubMed
    Score: 0.082
  14. Mutawi TM, Zedan MM, Yahya RS, Zakria MM, El-Sawi MR, Gaedigk A. Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. Pharmacogenomics. 2021 04; 22(6):323-334.
    View in: PubMed
    Score: 0.082
  15. Desta Z, El-Boraie A, Gong L, Somogyi AA, Lauschke VM, Dandara C, Klein K, Miller NA, Klein TE, Tyndale RF, Whirl-Carrillo M, Gaedigk A. PharmVar GeneFocus: CYP2B6. Clin Pharmacol Ther. 2021 07; 110(1):82-97.
    View in: PubMed
    Score: 0.081
  16. Turner AJ, Aggarwal P, Boone EC, Haidar CE, Relling MV, Derezinski AD, Broeckel U, Gaedigk A. Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. J Mol Diagn. 2021 05; 23(5):577-588.
    View in: PubMed
    Score: 0.081
  17. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Ag?ndez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021 02; 109(2):352-366.
    View in: PubMed
    Score: 0.078
  18. Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Ag?ndez JAG, Black JL, Dunnenberger HM, Ruano G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Gaedigk A. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020 01; 107(1):154-170.
    View in: PubMed
    Score: 0.074
  19. Gaedigk A, Whirl-Carrillo M, Pratt VM, Miller NA, Klein TE. PharmVar and the Landscape of Pharmacogenetic Resources. Clin Pharmacol Ther. 2020 01; 107(1):43-46.
    View in: PubMed
    Score: 0.074
  20. Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 01; 107(1):50-52.
    View in: PubMed
    Score: 0.074
  21. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020 01; 13(1):116-124.
    View in: PubMed
    Score: 0.074
  22. Gaedigk A, Turner A, Everts RE, Scott SA, Aggarwal P, Broeckel U, McMillin GA, Melis R, Boone EC, Pratt VM, Kalman LV. Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project. J Mol Diagn. 2019 11; 21(6):1034-1052.
    View in: PubMed
    Score: 0.073
  23. Gaedigk A. Pharmacogenetics: Chasing Perfection. Clin Pharmacol Ther. 2019 08; 106(2):265-270.
    View in: PubMed
    Score: 0.073
  24. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Twist GP, Klein TE, Miller NA. The Evolution of PharmVar. Clin Pharmacol Ther. 2019 01; 105(1):29-32.
    View in: PubMed
    Score: 0.069
  25. Yang JJ, Whirl-Carrillo M, Scott SA, Turner AJ, Schwab M, Tanaka Y, Suarez-Kurtz G, Schaeffeler E, Klein TE, Miller NA, Gaedigk A. Pharmacogene Variation Consortium Gene Introduction: NUDT15. Clin Pharmacol Ther. 2019 05; 105(5):1091-1094.
    View in: PubMed
    Score: 0.069
  26. Montan? Jaime LK, Paul J, Lalla A, Legall G, Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics. 2018 02; 19(3):197-212.
    View in: PubMed
    Score: 0.065
  27. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018 03; 103(3):399-401.
    View in: PubMed
    Score: 0.065
  28. Gaedigk A, Twist GP, Farrow EG, Lowry JA, Soden SE, Miller NA. In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Pharmacogenomics. 2017 Apr; 18(5):427-431.
    View in: PubMed
    Score: 0.062
  29. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
    View in: PubMed
    Score: 0.059
  30. Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metab Dispos. 2016 07; 44(7):948-58.
    View in: PubMed
    Score: 0.056
  31. Gaedigk A, Riffel AK, Leeder JS. CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele. J Mol Diagn. 2015 Nov; 17(6):740-8.
    View in: PubMed
    Score: 0.055
  32. Gaedigk A, Freeman N, Hartshorne T, Riffel AK, Irwin D, Bishop JR, Stein MA, Newcorn JH, Jaime LK, Cherner M, Leeder JS. SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum. Sci Rep. 2015 Mar 19; 5:9257.
    View in: PubMed
    Score: 0.054
  33. Gaedigk A, Riffel AK, Berrocal BG, Solaesa VG, D?vila I, Isidoro-Garc?a M. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test no-call in the clinical setting. Clin Chem Lab Med. 2014 Jun; 52(6):799-807.
    View in: PubMed
    Score: 0.051
  34. Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014 Jun; 15(8):1055-8.
    View in: PubMed
    Score: 0.051
  35. Gaedigk A, Garcia-Ribera C, Jeong HE, Shin JG, Hernandez-Sanchez J, Hernandez-Sanchez JT. Resolution of a clinical AmpliChip CYP450 Test? no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics. 2014 Jun; 15(9):1175-84.
    View in: PubMed
    Score: 0.051
  36. Gaedigk A, Leeder JS. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics. 2014 Mar; 15(4):407-10.
    View in: PubMed
    Score: 0.050
  37. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014 Feb; 15(2):218-32.
    View in: PubMed
    Score: 0.050
  38. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013 Oct; 25(5):534-53.
    View in: PubMed
    Score: 0.049
  39. Twist GP, Gaedigk R, Leeder JS, Gaedigk A. High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. Pharmacogenomics. 2013 Jun; 14(8):913-22.
    View in: PubMed
    Score: 0.047
  40. Montan? Jaime LK, Lalla A, Steimer W, Gaedigk A. Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics. 2013 Feb; 14(3):261-76.
    View in: PubMed
    Score: 0.046
  41. Sim SC, Daly AK, Gaedigk A. CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet Genomics. 2012 Sep; 22(9):692-4.
    View in: PubMed
    Score: 0.045
  42. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics. 2012 Jan; 13(1):91-111.
    View in: PubMed
    Score: 0.043
  43. Gaedigk A, Hernandez J, Garc?a-Solaesa V, S?nchez S, Isidoro-Garc?a M. Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls. Pharmacogenomics. 2011 Nov; 12(11):1617-22.
    View in: PubMed
    Score: 0.042
  44. Gaedigk A, Isidoro-Garc?a M, Pearce RE, S?nchez S, Garc?a-Solaesa V, Lorenzo-Romo C, Gonzalez-Tejera G, Corey S. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol. 2010 Sep; 66(9):859-64.
    View in: PubMed
    Score: 0.038
  45. Gaedigk A, Gaedigk R, Leeder JS. UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technology. Clin Chem Lab Med. 2010 May; 48(5):627-33.
    View in: PubMed
    Score: 0.038
  46. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos. 2010 Jun; 38(6):894-7.
    View in: PubMed
    Score: 0.038
  47. Gaedigk A, Fuhr U, Johnson C, B?rard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics. 2010 Jan; 11(1):43-53.
    View in: PubMed
    Score: 0.037
  48. Gaedigk A, Frank D, Fuhr U. Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. Eur J Clin Pharmacol. 2009 Jan; 65(1):97-100.
    View in: PubMed
    Score: 0.034
  49. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol. 2008 May; 64(5):465-75.
    View in: PubMed
    Score: 0.033
  50. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb; 83(2):234-42.
    View in: PubMed
    Score: 0.032
  51. Abdel-Rahman SM, Preuett B, Gaedigk A. Multilocus genotyping identifies infections by multiple strains of Trichophyton tonsurans. J Clin Microbiol. 2007 Jun; 45(6):1949-53.
    View in: PubMed
    Score: 0.031
  52. Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther. 2007 Jun; 81(6):817-20.
    View in: PubMed
    Score: 0.031
  53. Gaedigk A, Ndjountch? L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007 Feb; 81(2):242-51.
    View in: PubMed
    Score: 0.031
  54. Abdel-Rahman SM, Simon S, Wright KJ, Ndjountche L, Gaedigk A. Tracking Trichophyton tonsurans through a large urban child care center: defining infection prevalence and transmission patterns by molecular strain typing. Pediatrics. 2006 Dec; 118(6):2365-73.
    View in: PubMed
    Score: 0.030
  55. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, Leeder JS. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther. 2006 Nov; 319(2):523-32.
    View in: PubMed
    Score: 0.029
  56. Gaedigk A, Leeder JS. Comments on Hoskins et al. [(2005) drug metab dispos 33:1564-1565]. Drug Metab Dispos. 2006 Mar; 34(3):504-5; author reply 506.
    View in: PubMed
    Score: 0.029
  57. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos. 2006 Apr; 34(4):563-9.
    View in: PubMed
    Score: 0.028
  58. Gaedigk A, Gaedigk R, Leeder JS. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem Biophys Res Commun. 2005 Nov 04; 336(4):1241-50.
    View in: PubMed
    Score: 0.028
  59. Gaedigk A, Ndjountch? L, Leeder JS, Bradford LD. Limited association of the 2988g > a single nucleotide polymorphism with CYP2D641 in black subjects. Clin Pharmacol Ther. 2005 Mar; 77(3):228-30; author reply 230-1.
    View in: PubMed
    Score: 0.027
  60. Gaedigk A, Bhathena A, Ndjountch? L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, Rogan PK, Leeder JS. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005; 5(3):173-82.
    View in: PubMed
    Score: 0.026
  61. Wagner JB, Abdel-Rahman S, Raghuveer G, Gaedigk A, Boone EC, Gaedigk R, Staggs VS, Reed GA, Zhang N, Leeder JS. SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes (Basel). 2024 Jan 15; 15(1).
    View in: PubMed
    Score: 0.025
  62. Gaedigk A, Gaedigk R, Abdel-Rahman SM. Genetic Heterogeneity in the rRNA Gene Locus of Trichophyton tonsurans. J Clin Microbiol. 2003 Dec; 41(12):5478-87.
    View in: PubMed
    Score: 0.025
  63. Cramer EY, Bartlett J, Chan ER, Gaedigk A, Ratsimbasoa AC, Mehlotra RK, Williams SM, Zimmerman PA. Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism. Pharmacogenomics. 2023 07; 24(11):583-597.
    View in: PubMed
    Score: 0.024
  64. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023 09; 25(9):619-629.
    View in: PubMed
    Score: 0.024
  65. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 2003 Jun; 49(6 Pt 1):1008-11.
    View in: PubMed
    Score: 0.024
  66. Gaedigk A, Ndjountch? L, Gaedigk R, Leeder JS, Bradford LD. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther. 2003 Jun; 73(6):575-6.
    View in: PubMed
    Score: 0.024
  67. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
    View in: PubMed
    Score: 0.024
  68. Bunka M, Wong G, Kim D, Edwards L, Austin J, Doyle-Waters MM, Gaedigk A, Bryan S. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis. Psychiatry Res. 2023 03; 321:115102.
    View in: PubMed
    Score: 0.023
  69. Black K, Brenn BR, Gaedigk A, Wanderer JP, Van Driest SL. Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron. Clin Transl Sci. 2023 02; 16(2):269-278.
    View in: PubMed
    Score: 0.023
  70. Krzyzanski W, Stockard B, Gaedigk A, Scott A, Nolte W, Gibson K, Leeder JS, Lewis T. Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life. CPT Pharmacometrics Syst Pharmacol. 2023 01; 12(1):110-121.
    View in: PubMed
    Score: 0.023
  71. Leeder JS, Gaedigk A, Wright KJ, Staggs VS, Soden SE, Lin YS, Pearce RE. A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence. Clin Transl Sci. 2022 Oct; 15(10):2514-2527.
    View in: PubMed
    Score: 0.022
  72. Pratt VM, Wang WY, Boone EC, Broeckel U, Cody N, Edelmann L, Gaedigk A, Lynnes TC, Medeiros EB, Moyer AM, Mitchell MW, Scott SA, Starostik P, Turner A, Kalman LV. Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project. J Mol Diagn. 2022 10; 24(10):1079-1088.
    View in: PubMed
    Score: 0.022
  73. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2022 10; 24(10):1051-1063.
    View in: PubMed
    Score: 0.022
  74. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002 Jul; 72(1):76-89.
    View in: PubMed
    Score: 0.022
  75. Sunthankar SD, Kannankeril PJ, Gaedigk A, Radbill AE, Fish FA, Van Driest SL. Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clin Transl Sci. 2022 07; 15(7):1787-1795.
    View in: PubMed
    Score: 0.022
  76. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 05; 111(5):1007-1021.
    View in: PubMed
    Score: 0.022
  77. Chan ER, Mehlotra RK, Pirani KA, Ratsimbasoa AC, Williams SM, Gaedigk A, Zimmerman PA. CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study. Pharmacogenomics. 2022 04; 23(5):315-325.
    View in: PubMed
    Score: 0.022
  78. Feldman K, Kearns GL, Pearce RE, Abdel-Rahman SM, Steven Leeder J, Friesen A, Staggs VS, Gaedigk A, Weigel J, Shakhnovich V. Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children. Clin Transl Sci. 2022 05; 15(5):1155-1166.
    View in: PubMed
    Score: 0.022
  79. Tayeh MK, Gaedigk A, Goetz MP, Klein TE, Lyon E, McMillin GA, Rentas S, Shinawi M, Pratt VM, Scott SA. Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 04; 24(4):759-768.
    View in: PubMed
    Score: 0.022
  80. Leeder JS, Dinh JC, Gaedigk A, Staggs VS, Prasad B, Pearce RE. Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metab Dispos. 2022 01; 50(1):24-32.
    View in: PubMed
    Score: 0.021
  81. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001 Oct; 79(10):841-7.
    View in: PubMed
    Score: 0.021
  82. Hippman C, Slomp C, Morris E, Batallones R, Inglis A, Carrion P, Brain U, Higginson M, Wright GEB, Balneaves LG, Ryan D, Nislow C, Ross CJD, Gaedigk A, Oberlander TF, Austin J. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy. Arch Womens Ment Health. 2022 04; 25(2):355-365.
    View in: PubMed
    Score: 0.021
  83. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn. 2021 09; 23(9):1047-1064.
    View in: PubMed
    Score: 0.021
  84. Pratt VM, Turner A, Broeckel U, Dawson DB, Gaedigk A, Lynnes TC, Medeiros EB, Moyer AM, Requesens D, Vetrini F, Kalman LV. Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project. J Mol Diagn. 2021 08; 23(8):952-958.
    View in: PubMed
    Score: 0.021
  85. Carranza-Leon D, Dickson AL, Gaedigk A, Stein CM, Chung CP. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice. Pharmacogenomics J. 2021 08; 21(4):484-490.
    View in: PubMed
    Score: 0.020
  86. Hongkaew Y, Gaedigk A, Wilffert B, Ngamsamut N, Kittitharaphan W, Limsila P, Sukasem C. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep. 2021 02 18; 11(1):4158.
    View in: PubMed
    Score: 0.020
  87. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, M?ller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 10; 110(4):888-896.
    View in: PubMed
    Score: 0.020
  88. Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen LS, Cordner ZA, Deckert J, Degenhardt F, DeLisi LE, Folkersen L, Kennedy JL, Klein TE, McClay JL, McMahon FJ, Musil R, Saccone NL, Sangkuhl K, Stowe RM, Tan EC, Tiwari AK, Zai CC, Zai G, Zhang J, Gaedigk A, M?ller DJ. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2021 Jan; 54(1):5-17.
    View in: PubMed
    Score: 0.020
  89. McInnes G, Dalton R, Sangkuhl K, Whirl-Carrillo M, Lee SB, Tsao PS, Gaedigk A, Altman RB, Woodahl EL. Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Comput Biol. 2020 11; 16(11):e1008399.
    View in: PubMed
    Score: 0.020
  90. Roberts TA, Wagner JA, Sandritter T, Black BT, Gaedigk A, Stancil SL. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital. Clin Transl Sci. 2021 01; 14(1):412-421.
    View in: PubMed
    Score: 0.020
  91. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021 06; 109(6):1417-1423.
    View in: PubMed
    Score: 0.020
  92. Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, Caudle KE, Callaghan JT. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021 02; 109(2):302-309.
    View in: PubMed
    Score: 0.020
  93. Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
    View in: PubMed
    Score: 0.020
  94. Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Ag?ndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 08; 108(2):191-200.
    View in: PubMed
    Score: 0.019
  95. Wagner JB, Abdel-Rahman S, Gaedigk A, Gaedigk R, Raghuveer G, Staggs VS, Van Haandel L, Leeder JS. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Transl Sci. 2020 05; 13(3):628-637.
    View in: PubMed
    Score: 0.019
  96. Zhang H, Basit A, Wolford C, Chen KF, Gaedigk A, Lin YS, Leeder JS, Prasad B. Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years. Clin Pharmacol Ther. 2020 05; 107(5):1149-1158.
    View in: PubMed
    Score: 0.019
  97. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000 Feb; 38(2):61-8.
    View in: PubMed
    Score: 0.019
  98. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999 Dec; 9(6):669-82.
    View in: PubMed
    Score: 0.019
  99. Botton MR, Lu X, Zhao G, Repnikova E, Seki Y, Gaedigk A, Schadt EE, Edelmann L, Scott SA. Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. Hum Mutat. 2019 11; 40(11):e37-e51.
    View in: PubMed
    Score: 0.018
  100. Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity. Clin Transl Sci. 2020 01; 13(1):147-156.
    View in: PubMed
    Score: 0.018
  101. Boronat A, Mateus J, Soldevila-Domenech N, Guerra M, Rodr?guez-Morat? J, Varon C, Mu?oz D, Barbosa F, Morales JC, Gaedigk A, Langohr K, Covas MI, P?rez-Ma?? C, Fit? M, Tyndale RF, de la Torre R. Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial. Free Radic Biol Med. 2019 11 01; 143:471-481.
    View in: PubMed
    Score: 0.018
  102. Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019 10; 106(4):726-733.
    View in: PubMed
    Score: 0.018
  103. Ladumor MK, Bhatt DK, Gaedigk A, Sharma S, Thakur A, Pearce RE, Leeder JS, Bolger MB, Singh S, Prasad B. Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism. Drug Metab Dispos. 2019 08; 47(8):818-831.
    View in: PubMed
    Score: 0.018
  104. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 07; 106(1):94-102.
    View in: PubMed
    Score: 0.018
  105. Wagner JB, Abdel-Rahman S, Gaedigk R, Gaedigk A, Raghuveer G, Staggs VS, Kauffman R, Van Haandel L, Leeder JS. Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Pharmacol Ther. 2019 06; 105(6):1501-1512.
    View in: PubMed
    Score: 0.018
  106. Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8.
    View in: PubMed
    Score: 0.017
  107. Qiao W, Martis S, Mendiratta G, Shi L, Botton MR, Yang Y, Gaedigk A, Vijzelaar R, Edelmann L, Kornreich R, Desnick RJ, Scott SA. Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics. 2019 01; 20(1):9-20.
    View in: PubMed
    Score: 0.017
  108. Gammal RS, Caudle KE, Quinn CT, Wang WC, Gaedigk A, Prows CA, Haidar CE, Taylor AK, Klein TE, Sangkuhl K, Hankins JS, Crews KR. The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children. Clin Pharmacol Ther. 2019 06; 105(6):1300-1302.
    View in: PubMed
    Score: 0.017
  109. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CMT, van den Anker JN. Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clin Pharmacokinet. 2018 10; 57(10):1325-1336.
    View in: PubMed
    Score: 0.017
  110. Shakhnovich V, Abdel-Rahman S, Friesen CA, Weigel J, Pearce RE, Gaedigk A, Leeder JS, Kearns GL. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes. 2019 01; 14(1).
    View in: PubMed
    Score: 0.017
  111. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics. 1998 Aug; 8(4):305-13.
    View in: PubMed
    Score: 0.017
  112. Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, Choudhari P, Boberg M, Pearce RE, Gaedigk R, Broeckel U, Leeder JS, Prasad B. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. Clin Pharmacol Ther. 2019 01; 105(1):131-141.
    View in: PubMed
    Score: 0.017
  113. Chamnanphon M, Gaedigk A, Vanwong N, Nuntamool N, Hongkaew Y, Puangpetch A, Sukasem C. CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics. 2018 08 01; 19(12):947-960.
    View in: PubMed
    Score: 0.017
  114. Lee SB, Wheeler MM, Patterson K, McGee S, Dalton R, Woodahl EL, Gaedigk A, Thummel KE, Nickerson DA. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med. 2019 02; 21(2):361-372.
    View in: PubMed
    Score: 0.017
  115. Leeder JS, Lu X, Timsit Y, Gaedigk A. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics. 1998 Jun; 8(3):211-25.
    View in: PubMed
    Score: 0.017
  116. Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metab Dispos. 2018 06; 46(6):888-896.
    View in: PubMed
    Score: 0.017
  117. Wagner JB, Abdel-Rahman S, Van Haandel L, Gaedigk A, Gaedigk R, Raghuveer G, Kauffman R, Leeder JS. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 06; 58(6):823-833.
    View in: PubMed
    Score: 0.016
  118. Gaedigk A, Lekas P, Berchuk M, Grant DM. Novel sulfotransferases cloned by RT-PCR: real proteins or PCR artifacts? Chem Biol Interact. 1998 Feb 20; 109(1-3):43-52.
    View in: PubMed
    Score: 0.016
  119. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
    View in: PubMed
    Score: 0.016
  120. Gaedigk A, Leeder JS, Grant DM. Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase. DNA Cell Biol. 1997 Nov; 16(11):1257-66.
    View in: PubMed
    Score: 0.016
  121. Burgess KS, Ipe J, Swart M, Metzger IF, Lu J, Gufford BT, Thong N, Desta Z, Gaedigk R, Pearce RE, Gaedigk A, Liu Y, Skaar TC. Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. Clin Pharmacol Ther. 2018 07; 104(1):130-138.
    View in: PubMed
    Score: 0.016
  122. McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS. Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM R. 2018 03; 10(3):235-243.
    View in: PubMed
    Score: 0.016
  123. Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B. Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. J Pharmacol Exp Ther. 2017 11; 363(2):265-274.
    View in: PubMed
    Score: 0.016
  124. Bhatt DK, Gaedigk A, Pearce RE, Leeder JS, Prasad B. Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. Drug Metab Dispos. 2017 09; 45(9):1044-1048.
    View in: PubMed
    Score: 0.016
  125. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 08; 102(2):213-218.
    View in: PubMed
    Score: 0.015
  126. Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, Gaedigk A, Pepper MS. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics. 2017 Apr; 18(5):433-443.
    View in: PubMed
    Score: 0.015
  127. Gaedigk A, Beatty BG, Grant DM. Cloning, structural organization, and chromosomal mapping of the human phenol sulfotransferase STP2 gene. Genomics. 1997 Mar 01; 40(2):242-6.
    View in: PubMed
    Score: 0.015
  128. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M?ller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07; 102(1):37-44.
    View in: PubMed
    Score: 0.015
  129. Boberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, Leeder JS, Prasad B. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Drug Metab Dispos. 2017 02; 45(2):216-223.
    View in: PubMed
    Score: 0.015
  130. Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD. Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther. 2016 10; 100(4):362-70.
    View in: PubMed
    Score: 0.015
  131. S?nchez-Mart?n A, S?nchez-Iglesias S, Garc?a-Berrocal B, Lorenzo C, Gaedigk A, Isidoro-Garc?a M. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics. 2016 08; 17(12):1291-3.
    View in: PubMed
    Score: 0.015
  132. Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metab Dispos. 2016 07; 44(7):1070-9.
    View in: PubMed
    Score: 0.014
  133. S?nchez-Iglesias S, Garc?a-Solaesa V, Garc?a-Berrocal B, Sanchez-Mart?n A, Lorenzo-Romo C, Mart?n-Pinto T, Gaedigk A, Gonz?lez-Buitrago JM, Isidoro-Garc?a M. Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (Baltimore). 2016 Feb; 95(6):e2473.
    View in: PubMed
    Score: 0.014
  134. Shah RR, Gaedigk A, LLerena A, Eichelbaum M, Stingl J, Smith RL. CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics. 2016 Feb; 17(3):259-75.
    View in: PubMed
    Score: 0.014
  135. Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2016 06; 99(6):642-50.
    View in: PubMed
    Score: 0.014
  136. Qiao W, Yang Y, Sebra R, Mendiratta G, Gaedigk A, Desnick RJ, Scott SA. Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Hum Mutat. 2016 Mar; 37(3):315-23.
    View in: PubMed
    Score: 0.014
  137. Kalman LV, Ag?ndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, M?ller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016 Feb; 99(2):172-85.
    View in: PubMed
    Score: 0.014
  138. Dodgen TM, Labuschagne CJ, van Schalkwyk A, Steffens FE, Gaedigk A, Cromarty AD, Alessandrini M, Pepper MS. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J. 2016 11; 16(6):566-572.
    View in: PubMed
    Score: 0.014
  139. Burgess KS, Philips S, Benson EA, Desta Z, Gaedigk A, Gaedigk R, Segar MW, Liu Y, Skaar TC. Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver. Clin Pharmacol Ther. 2015 Aug; 98(2):205-15.
    View in: PubMed
    Score: 0.014
  140. Hicks JK, Bishop JR, Sangkuhl K, M?ller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug; 98(2):127-34.
    View in: PubMed
    Score: 0.014
  141. Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics. 2014 Dec; 15(16):1947-62.
    View in: PubMed
    Score: 0.013
  142. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics. 1994 Jun; 4(3):142-53.
    View in: PubMed
    Score: 0.013
  143. Lalan S, Abdel-Rahman S, Gaedigk A, Leeder JS, Warady BA, Dai H, Blowey D. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol. 2014 Oct; 29(10):2039-49.
    View in: PubMed
    Score: 0.013
  144. He Y, Brunstrom-Hernandez JE, Thio LL, Lackey S, Gaebler-Spira D, Kuroda MM, Stashinko E, Hoon AH, Vargus-Adams J, Stevenson RD, Lowenhaupt S, McLaughlin JF, Christensen A, Dosa NP, Butler M, Schwabe A, Lopez C, Roge D, Kennedy D, Tilton A, Krach LE, Lewandowski A, Dai H, Gaedigk A, Leeder JS, Jusko WJ. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. J Pediatr. 2014 May; 164(5):1181-1188.e8.
    View in: PubMed
    Score: 0.012
  145. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 Apr; 95(4):376-82.
    View in: PubMed
    Score: 0.012
  146. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014 Jan 01; 23(1):268-78.
    View in: PubMed
    Score: 0.012
  147. Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, Li L, Flockhart DA, Skaar TC. Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos. 2013 Oct; 41(10):1763-8.
    View in: PubMed
    Score: 0.012
  148. Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics. 2013 Aug; 23(8):403-14.
    View in: PubMed
    Score: 0.012
  149. Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clin Toxicol (Phila). 2013 Aug; 51(7):540-4.
    View in: PubMed
    Score: 0.012
  150. Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P, Dr?gem?ller BI, Wright GE, Warnich L, Labuschagne CD, van Schalkwyk A, Gaedigk A, Pepper MS. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013 Jan 29; 14:20.
    View in: PubMed
    Score: 0.012
  151. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M?ller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May; 93(5):402-8.
    View in: PubMed
    Score: 0.012
  152. Myers AL, Gaedigk A, Dai H, James LP, Jones BL, Neville KA. Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J. 2012 May; 31(5):464-8.
    View in: PubMed
    Score: 0.011
  153. Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, Flockhart DA, Skaar TC. In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4a expression. Drug Metab Dispos. 2012 Apr; 40(4):726-33.
    View in: PubMed
    Score: 0.011
  154. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb; 91(2):321-6.
    View in: PubMed
    Score: 0.011
  155. Mann A, Miksys SL, Gaedigk A, Kish SJ, Mash DC, Tyndale RF. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging. 2012 Sep; 33(9):2160-71.
    View in: PubMed
    Score: 0.011
  156. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet. 1991 May; 48(5):943-50.
    View in: PubMed
    Score: 0.010
  157. Madadi P, Ciszkowski C, Gaedigk A, Leeder JS, Teitelbaum R, Chitayat D, Koren G. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf. 2011 Feb 01; 6(1):36-9.
    View in: PubMed
    Score: 0.010
  158. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther. 2010 Nov; 88(5):643-51.
    View in: PubMed
    Score: 0.010
  159. Gonz?lez-Tejera G, Gaedigk A, Corey S. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. P R Health Sci J. 2010 Sep; 29(3):299-304.
    View in: PubMed
    Score: 0.010
  160. Wright GE, Niehaus DJ, Dr?gem?ller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010 Jul; 74(4):340-50.
    View in: PubMed
    Score: 0.010
  161. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010 Aug; 20(8):1020-36.
    View in: PubMed
    Score: 0.010
  162. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol. 2010 May; 66(5):475-85.
    View in: PubMed
    Score: 0.009
  163. Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther. 2008 Dec; 84(6):674-8.
    View in: PubMed
    Score: 0.009
  164. Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C, Gaedigk A, Leeder JS, McEvoy JP, Weale ME, Goldstein DB. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med. 2008 Oct; 10(10):720-9.
    View in: PubMed
    Score: 0.009
  165. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008 Sep; 48(9):1041-51.
    View in: PubMed
    Score: 0.009
  166. Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther. 2008 Sep; 30(9):1687-99.
    View in: PubMed
    Score: 0.009
  167. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan; 85(1):31-5.
    View in: PubMed
    Score: 0.009
  168. Kearns GL, Blumer J, Schexnayder S, James LP, Adcock KG, Reed MD, Daniel JF, Gaedigk A, Paul J. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol. 2008 Nov; 48(11):1356-65.
    View in: PubMed
    Score: 0.008
  169. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar; 82(3):155-65.
    View in: PubMed
    Score: 0.008
  170. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr; 81(4):510-6.
    View in: PubMed
    Score: 0.008
  171. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, Teitelbaum R, Karaskov T, Aleksa K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician. 2007 Jan; 53(1):33-5.
    View in: PubMed
    Score: 0.008
  172. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19; 368(9536):704.
    View in: PubMed
    Score: 0.007
  173. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Jun; 31(6):1274-85.
    View in: PubMed
    Score: 0.007
  174. Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol. 2006 Jun; 62(6):431-6.
    View in: PubMed
    Score: 0.007
  175. Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr; 50(4):1130-5.
    View in: PubMed
    Score: 0.007
  176. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol. 2005 Dec; 45(12):1413-21.
    View in: PubMed
    Score: 0.007
  177. Luo HR, Gaedigk A, Aloumanis V, Wan YJ. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol. 2005 Dec; 61(11):797-802.
    View in: PubMed
    Score: 0.007
  178. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug; 314(2):626-35.
    View in: PubMed
    Score: 0.007
  179. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004 Dec; 76(6):536-44.
    View in: PubMed
    Score: 0.007
  180. Kim MJ, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS. Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol. 2004 Sep; 44(9):966-73.
    View in: PubMed
    Score: 0.006
  181. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15; 36(5):1034-40.
    View in: PubMed
    Score: 0.006
  182. Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 Jun; 44(6):570-6.
    View in: PubMed
    Score: 0.006
  183. Kennedy MJ, Scripture CD, Kashuba AD, Scott CS, Gaedigk A, Kearns GL. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther. 2004 Mar; 75(3):163-71.
    View in: PubMed
    Score: 0.006
  184. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
    View in: PubMed
    Score: 0.006
  185. Kearns GL, Andersson T, James LP, Gaedigk A, Kraynak RA, Abdel-Rahman SM, Ramabadran K, van den Anker JN. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol. 2003 Aug; 43(8):840-8.
    View in: PubMed
    Score: 0.006
  186. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002 Aug; 22(8):1001-6.
    View in: PubMed
    Score: 0.006
  187. Kim MJ, Bertino JS, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002 Aug; 72(2):192-9.
    View in: PubMed
    Score: 0.006
  188. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol. 2002 Jan; 42(1):24-9.
    View in: PubMed
    Score: 0.005
  189. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul; 41(7):715-22.
    View in: PubMed
    Score: 0.005
  190. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
    View in: PubMed
    Score: 0.005
  191. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000 Mar; 54(1):19-29.
    View in: PubMed
    Score: 0.005
  192. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther. 1999 Nov; 66(5):535-41.
    View in: PubMed
    Score: 0.005
  193. Bidwell LM, McManus ME, Gaedigk A, Kakuta Y, Negishi M, Pedersen L, Martin JL. Crystal structure of human catecholamine sulfotransferase. J Mol Biol. 1999 Oct 29; 293(3):521-30.
    View in: PubMed
    Score: 0.005
  194. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
    View in: PubMed
    Score: 0.005
  195. Brix LA, Duggleby RG, Gaedigk A, McManus ME. Structural characterization of human aryl sulphotransferases. Biochem J. 1999 Jan 15; 337 ( Pt 2):337-43.
    View in: PubMed
    Score: 0.004
  196. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998 Oct; 8(5):403-10.
    View in: PubMed
    Score: 0.004
  197. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics. 1998 Aug; 8(4):325-33.
    View in: PubMed
    Score: 0.004
  198. Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 1998 Jun 12; 710(1-2):143-8.
    View in: PubMed
    Score: 0.004
  199. Bidwell LM, Gillam EM, Gaedigk A, Zhu X, Grant D, McManus ME. Bacterial expression of two human aryl sulfotransferases. Chem Biol Interact. 1998 Feb 20; 109(1-3):137-41.
    View in: PubMed
    Score: 0.004
  200. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, M?rike K, St?ven T, Eichelbaum M. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998 Feb; 8(1):15-26.
    View in: PubMed
    Score: 0.004
  201. Bradford LD, Gaedigk A, Leeder JS. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998; 34(4):797-804.
    View in: PubMed
    Score: 0.004
  202. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997 May 12; 376(1-2):61-70.
    View in: PubMed
    Score: 0.004
  203. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res. 1997 May 12; 376(1-2):153-60.
    View in: PubMed
    Score: 0.004
  204. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol. 1996 Feb; 49(2):234-43.
    View in: PubMed
    Score: 0.004
  205. Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol. 1995 Oct 26; 50(9):1353-9.
    View in: PubMed
    Score: 0.003
  206. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991 Oct; 10(8):545-58.
    View in: PubMed
    Score: 0.003
  207. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 1990 Oct 25; 347(6295):773-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.